Diabetes research and clinical practice最新文献

{"title":"Pharmacological interventions for smoking cessation in Type 2 diabetes: A systematic review with meta-analysis and GRADE evaluation","authors":"Alison Martin ,&nbsp;Giusy Rita Maria La Rosa ,&nbsp;Hannah Rice ,&nbsp;Andrea Bertuzzi ,&nbsp;Michal Witkowski ,&nbsp;Erika Anastasi ,&nbsp;Giulio Geraci ,&nbsp;Riccardo Polosa ,&nbsp;the DiaSmokeFree Working Group","doi":"10.1016/j.diabres.2025.112202","DOIUrl":"10.1016/j.diabres.2025.112202","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the efficacy and safety of pharmacological therapies for smoking cessation in individuals with Type 2 Diabetes Mellitus (T2DM) through a systematic review, <em>meta</em>-analysis, and GRADE evaluation.</div></div><div><h3>Methods</h3><div>PubMed and Scopus were searched on 7 June 2024 using relevant keywords. Randomized controlled trials and prospective cohort studies involving adult smokers with T2DM receiving pharmacological treatments for smoking cessation were included. Data were extracted independently by two reviewers. Random-effects <em>meta</em>-analyses were conducted, and the certainty of evidence was assessed using GRADE.</div></div><div><h3>Results</h3><div>Eighteen studies (19 publications) were included. Pharmacotherapy significantly increased continuous abstinence rates at 12 and 24 weeks (p &lt; 0.001), with ORs of 4.17 (95 % CI: 2.71–6.42) and 3.80 (95 % CI: 2.52–5.72), respectively. At 52 weeks, varenicline was more effective than placebo (OR: 2.84, 95 % CI: 1.41–5.69, p = 0.003). Adverse events were more frequent with varenicline, but not significantly (OR: 1.40, 95 % CI: 0.98–1.98, p = 0.06).</div></div><div><h3>Conclusions</h3><div>Varenicline appears effective for smoking cessation in T2DM, with an acceptable tolerability profile. Bupropion and NRT show potential efficacy. However, most evidence comes from post hoc analyses in which diabetes was not a predefined variable, warranting cautious interpretation.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112202"},"PeriodicalIF":6.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143891804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study","authors":"Tien-Hsing Chen ,&nbsp;Te-Hsiung Wang ,&nbsp;Ming-Lung Tsai ,&nbsp;Ming-Shyan Lin ,&nbsp;Tzu-Hsien Tsai ,&nbsp;Tien-Shin Chou ,&nbsp;Chin-Ju Tseng ,&nbsp;Jhih-Wei Dai ,&nbsp;Chien-Wei Cheng ,&nbsp;Ning-I Yang ,&nbsp;Ming-Jui Hung ,&nbsp;Yuan Lin","doi":"10.1016/j.diabres.2025.112205","DOIUrl":"10.1016/j.diabres.2025.112205","url":null,"abstract":"<div><h3>Aims</h3><div>Limited evidence exists regarding the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in cardiovascular and renal outcomes in patients with advanced chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) &lt; 30 mL/min per 1.73 m².</div></div><div><h3>Methods</h3><div>We enrolled patients with type 2 diabetes mellitus and eGFR &lt; 30 mL/min per 1.73 m² who were prescribed SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i) from 2016 to 2022 (n = 117,924). The primary cardiovascular outcomes included cardiovascular death, myocardial infarction, ischemic stroke, and heart failure-related admission. Renal outcomes encompassed an eGFR decline of &gt;50 %, a doubling of serum creatinine levels, and progression to dialysis.</div></div><div><h3>Results</h3><div>The study included 6,730 participants [SGLT2i, n = 1,086; DPP4i, n = 5,644]. In both groups, the composite cardiovascular events developed at a rate of 13.2 events per 100 person-years (PYs) [hazard ratio (HR), 0.92; 95 % confidence interval (CI) 0.71–1.19]. The composite of renal events occurred at a rate of 18.5 and 16.2 events per 100 PYs in the SGLT2i and DPP4i groups, respectively [subdistribution HR 1.12; 95 % CI 0.91–1.38].</div></div><div><h3>Conclusions</h3><div>Compared to DPP4i, SGLT2i did not show superiority in the reduction of cardiovascular or renal events in CKD stage 4–5 patients.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112205"},"PeriodicalIF":6.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief report: Validity of self-report measures of medication adherence in young adults with youth-onset type 2 diabetes","authors":"Paula M. Trief ,&nbsp;Brian Burke ,&nbsp;Seth Kalichman ,&nbsp;Barbara J. Anderson ,&nbsp;Xun Liu ,&nbsp;Jane D. Bulger ,&nbsp;Ruth S. Weinstock","doi":"10.1016/j.diabres.2025.112201","DOIUrl":"10.1016/j.diabres.2025.112201","url":null,"abstract":"<div><div>Poor medication adherence is a significant concern in young adults with youth-onset type 2 diabetes. We examined the validity of three self-report adherence measures in comparison to unannounced telephone pill counts, and HbA1c. Results identified two valid measures that may be useful screeners to identify those struggling with medication adherence.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112201"},"PeriodicalIF":6.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic crosstalk and therapeutic interplay between diabetes and hyperuricemia","authors":"Tianshu Yang ,&nbsp;Lingyun Luo ,&nbsp;Xuelian Luo ,&nbsp;Xiaolei Liu","doi":"10.1016/j.diabres.2025.112204","DOIUrl":"10.1016/j.diabres.2025.112204","url":null,"abstract":"<div><div>Hyperuricemia and diabetes mellitus (DM) are prevalent metabolic disorders with high comorbidity, imposing a substantial global public health burden. Their coexistence is not merely additive but synergistic, exacerbating metabolic dysregulation through mechanisms such as insulin resistance and β-cell apoptosis, ultimately establishing a vicious cycle. Both disorders induce acute and chronic damage to vital organs, particularly the cardiovascular, renal systems. Hyperuricemia aggravates diabetic complications, notably diabetic cardiomyopathy, nephropathy and retinopathy via oxidative stress, inflammation, and metabolic dysregulation.<!--> <!-->Current urate-lowering therapies (ULTs), such as xanthine oxidase inhibitors and urate transporter 1 (URAT1, also known as SLC22A12) antagonists, demonstrate potential benefits in ameliorating diabetic complications but face challenges including safety concerns and dose adjustments. Similarly, several glucose-lowering drugs also exhibit the benefits of improving hyperuricemia. This review summarizes the metabolic crosstalk and therapeutic interplay between hyperuricemia and DM, examines the pathogenic role of uric acid in diabetic complications, and discusses the benefits and challenges of existing ULTs and glucose-lowering drugs in disrupting this cycle of metabolic dysregulation and concurrent organ damage. We hope our findings deepen the comprehension of the intricate metabolic crosstalk between glucose and urate homeostasis, providing novel therapeutic insights for patients with comorbid DM and hyperuricemia.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112204"},"PeriodicalIF":6.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143891805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal amount of vigorous-intensity physical activity for lowering incidence of microvascular diseases: A prospective cohort study from the UK Biobank","authors":"Lan Yu ,&nbsp;Guangbin Sun ,&nbsp;Yinyue Liu ,&nbsp;Dongfang Zhang ,&nbsp;Xiang Li ,&nbsp;Qiang Zhang ,&nbsp;Xiaolong Xing ,&nbsp;Xumei Zhang ,&nbsp;Xueli Yang","doi":"10.1016/j.diabres.2025.112203","DOIUrl":"10.1016/j.diabres.2025.112203","url":null,"abstract":"<div><h3>Aims</h3><div>To explore the amount–response associations between the duration of physical activity (PA) at different intensities and the risks of microvascular diseases (MVDs), with a particular focus on identifying the optimal amount of vigorous-intensity PA (VPA).</div></div><div><h3>Methods</h3><div>In this prospective cohort study, PA of different intensities were measured using wrist-worn accelerometers. MVDs, including nephropathy, neuropathy, and retinopathy, were identified from hospital inpatient records. Cox models and restricted cubic splines were used to evaluate the associations.</div></div><div><h3>Results</h3><div>This prospective study included 92,275 participants (40,256 males and 52,019 females) with a mean (SD) age of 61.7 (7.8) years. During a median follow-up of 7.9 years, a total of 5,201 individuals were diagnosed with MVDs, including 2,385 with nephropathy, 512 with neuropathy, and 2,666 with retinopathy. An L-shaped amount–response association for VPA and overall MVDs was observed (<em>P</em> value for non-linearity &lt; 0.001), with the optimal amount of 38 (95 % CI: 34, 44) minutes/week, corresponding to an HR of 0.71 (95 % CI: 0.64, 0.77).</div></div><div><h3>Conclusion</h3><div>VPA of 34–44 min/week were associated with 23 %-36 % lower risks of overall MVDs, with a less pronounced decline in risk thereafter. These findings may have implications for the future revision of physical activity recommendations to better improve microvascular health.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112203"},"PeriodicalIF":6.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143891806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing β-Cell plasticity and weight loss Thresholds in Long-Standing type 2 diabetes remission","authors":"Yadi Li ,&nbsp;Zheng Wei ,&nbsp;Xinmin Deng","doi":"10.1016/j.diabres.2025.112198","DOIUrl":"10.1016/j.diabres.2025.112198","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112198"},"PeriodicalIF":6.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma proteomic signatures for type 2 diabetes and related traits in the UK Biobank cohort","authors":"Trisha P. Gupte ,&nbsp;Zahra Azizi ,&nbsp;Pik Fang Kho ,&nbsp;Jiayan Zhou ,&nbsp;Kevin Nzenkue ,&nbsp;Ming-Li Chen ,&nbsp;Daniel J. Panyard ,&nbsp;Rodrigo Guarischi-Sousa ,&nbsp;Austin T. Hilliard ,&nbsp;Disha Sharma ,&nbsp;Kathleen Watson ,&nbsp;Fahim Abbasi ,&nbsp;Philip S. Tsao ,&nbsp;Shoa L. Clarke ,&nbsp;Themistocles L. Assimes","doi":"10.1016/j.diabres.2025.112194","DOIUrl":"10.1016/j.diabres.2025.112194","url":null,"abstract":"<div><h3>Objective</h3><div>The plasma proteome holds promise as a diagnostic and prognostic tool that can accurately reflect complex human traits and disease processes. We assessed the ability of proteins to predict type 2 diabetes and related traits.</div></div><div><h3>Study design</h3><div>We analyzed clinical, genetic, and proteomic data from three UK Biobank subcohorts for associations with truncal fat, estimated maximum oxygen consumption (VO₂max), and type 2 diabetes. Using least absolute shrinkage and selection operator (LASSO) regression, we compared predictive performance of each trait between data types. The benefit of proteomic signatures (PSs) over the type 2 diabetes clinical risk score, QDiabetes was evaluated. Two-sample Mendelian randomization (MR) identified potentially causal proteins for each trait. Results: LASSO-derived PSs improved prediction of truncal fat and VO₂max over clinical and genetic factors. We observed a modest improvement in type 2 diabetes prediction over the QDiabetes score when combining a PS derived for type 2 diabetes that was further augmented with fat- and fitness-associated PSs. Two-sample MR identified a few proteins as potentially causal for each trait.</div></div><div><h3>Conclusion</h3><div>Plasma PSs modestly improve type 2 diabetes prediction beyond clinical and genetic factors. Candidate causally associated proteins deserve further study as potential novel therapeutic targets for type 2 diabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112194"},"PeriodicalIF":6.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between disease acceptance and dietary adherence in patients with type 2 diabetes mellitus in China: a cross-sectional study","authors":"Xiao Liu ,&nbsp;Qiran Zhang ,&nbsp;Liu Huang ,&nbsp;Yuhuan Zhuang","doi":"10.1016/j.diabres.2025.112196","DOIUrl":"10.1016/j.diabres.2025.112196","url":null,"abstract":"<div><div>Studies on the correlation between dietary adherence in patients with Type 2 diabetes mellitus (T2DM) have focused on self-management, efficacy, and exercise. Limited empirical research on the impact of disease acceptance on dietary adherence. However, previous studies had shown that disease acceptance was an important factor influencing patients’ self-management behavior, of which dietary management was a key component. Therefore, it is of great significance to explore the relationship between disease acceptance and dietary adherence for the later development of relevant measures to improve dietary adherence.</div></div><div><h3>Aims</h3><div>The aim of this study was to investigate and report disease acceptance and diet adherence, as well as the factors that influenced diet adherence in patients with T2DM in China.</div></div><div><h3>Methods</h3><div>A descriptive study including 230 patients with T2DM was conducted in China. General socio-demographic data questionnaires, the Acceptance of Illness Scale (AIS), and the Dietary Adherence Scale (DAS) were used to explore the disease acceptance, dietary adherence. Correlation analyses were performed to determine the relationship between disease acceptance and dietary adherence, and logistic regression analyses were performed to determine the factors that contributed to dietary adherence in patients with T2DM.</div></div><div><h3>Results</h3><div>The mean score of disease acceptance was found to be (24.50 ± 7.34), and the mean score of dietary adherence was (78.79 ± 13.32). Correlation analysis indicated that disease acceptance was significantly and positively correlated with dietary adherence (r = 0.235, p ≤ 0.05). Further, regression analysis revealed that disease acceptance, gender, current treatment, and occupation were predictive of dietary adherence in patients with T2DM (R² = 0.124, F = 16.233).</div><div>Conclusion.</div><div>A greater acceptance of illness correlated with increased dietary adherence in patients with T2DM. Influences on dietary adherence were found to be multifaceted, encompassing socio-demographic data, disease-related factors, and disease acceptance. As such, targeted interventions may be enacted to enhance disease acceptance, thus improving the dietary adherence in patients with T2DM.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112196"},"PeriodicalIF":6.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients","authors":"Ting-Hui Liu ,&nbsp;Yu-Min Lin ,&nbsp;Tsung Yu ,&nbsp;Jheng-Yan Wu ,&nbsp;Chih-Cheng Lai","doi":"10.1016/j.diabres.2025.112197","DOIUrl":"10.1016/j.diabres.2025.112197","url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigated the neuroprotective effects of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in reducing dementia risk among older adults with type 2 diabetes mellitus (T2DM), compared to dipeptidyl peptidase-4 inhibitors (DPP4i).</div></div><div><h3>Methods</h3><div>Using the TriNetX electronic health records network, we conducted a retrospective cohort study including adults aged ≥65 years with T2DM who initiated SGLT2i or DPP4i between January 1, 2013, and November 30, 2024. Propensity score matching was employed to create two balanced cohorts, with the primary outcome being new-onset dementia. Secondary outcomes included dementia-related drug use and subtypes of dementia, such as Alzheimer’s disease and vascular dementia.</div></div><div><h3>Results</h3><div>After propensity score matching, 80,376 patients were included in each group. SGLT2i use was associated with a significantly lower risk of developing dementia compared to DPP4i (hazard ratio [HR], 0.54; 95 % confidence interval [CI]: 0.51–0.57; p &lt; 0.001). Similar reductions were observed for dementia-related drug use (HR, 0.69; 95 % CI: 0.64–0.74; p &lt; 0.001), Alzheimer’s disease (HR, 0.53; 95 % CI: 0.48–0.60; p &lt; 0.001), and vascular dementia (HR, 0.52; 95 % CI: 0.46–0.58; p &lt; 0.001). Subgroup analyses showed consistent protective effects.</div></div><div><h3>Conclusion</h3><div>Compared to DPP-4i, SGLT2i use is associated with a lower risk of dementia in older adults with T2DM, with consistent benefits observed across diverse populations and patient subgroups. These findings highlight the potential of SGLT2i as a preventive strategy for cognitive decline and support further investigation in randomized controlled trials.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112197"},"PeriodicalIF":6.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in diabetes screening and exercise during the COVID-19 pandemic in adults with prediabetes","authors":"Luis A. Rodriguez ,&nbsp;Maher Yassin ,&nbsp;O.Kenrik Duru ,&nbsp;Romain S. Neugebauer ,&nbsp;Susan D. Brown ,&nbsp;Yelba Castellon-Lopez ,&nbsp;Tainayah W. Thomas ,&nbsp;Julie A. Schmittdiel","doi":"10.1016/j.diabres.2025.112195","DOIUrl":"10.1016/j.diabres.2025.112195","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate changes in type 2 diabetes mellitus (T2DM) screening and exercise during the COVID-19 shelter-in-place, and whether Medicaid patients and racial/ethnic minoritized groups were disproportionally affected.</div></div><div><h3>Methods</h3><div>Retrospective cohort study of 578,585 adults with prediabetes aged ≥ 18–89 years with BMI ≥ 25 (≥23 if Asian) at Kaiser Permanente Northern California from January 2019 to December 2021. We used separate interrupted time-series analyses of aggregated weekly T2DM screening rates, or mean exercise minutes, to evaluate any decrease associated with the shelter-in-place (March 19, 2020, to June 1, 2020). Analyses were performed in 2023–2024.</div></div><div><h3>Results</h3><div>Before Covid, 121/10,000 patients/week were screened for T2DM, and patients exercised 107 min/week. Initially, screening dropped to near zero (by ∼ 96 %) followed by a slow increase of 7.4 (95 % CI: 2.4–12.4, <em>p</em>-value 0.004)/10,000 patients/week during the shelter-in-place. Similarly, exercise decreased initially by 37 (29–45, <em>p</em>-value &lt; 0.001) minutes/week, followed by a slow increase of 3.5 (1.7–5.4, <em>p</em>-value &lt; 0.001) minutes/week during the shelter-in-place. These patterns were similar across racial/ethnic groups; however, Medicaid patients took 1.5 years to resume baseline exercise levels.</div></div><div><h3>Conclusions</h3><div>The shelter-in-place was associated with an abrupt decrease in T2DM screening and exercise among adults with prediabetes. Future mandates should support high-risk populations, especially Medicaid, to maintain T2DM screening and exercise to prevent T2DM progression.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"224 ","pages":"Article 112195"},"PeriodicalIF":6.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}